Tilray Medical, a division of Tilray Brands, Inc. announced the publication of a scientific study. This new research focuses on comparing the bioavailability of different cannabinoid formulations, taking a step forward in understanding of medical cannabis. The study aimed to assess the pharmacokinetic parameters and relative bioavailability of two D9-tetrahydrocannabinol: cannabidiol (THC:CBD) formulations.
(A) An orally administered: Tilray THC:CBD extract and (B) an oromucosally administered nabiximols formulation. This pilot crossover study counterbalanced (1) 1mL of orally administered Tilray THC:CBD extraction (10 mg/mL each of THC and CBD) and (2) oromucosally administered sniximols (four sprays of 2.7 mg THC and 2.5 mg CBD per spray, for a total dose of 10.8 mg THC and 10 mg CBD). Tilray Medical is a leading provider of EU-GMP certified and pharmaceutical-grade medical cannabis products, having supplied over 20 countries with a comprehensive portfolio of THC and CBD products.
Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia, and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders.
